A large-scale proteomic analysis of 404 cervical cancer samples identified three molecular subtypes of squamous cell carcinoma with distinct prognoses and implicated CCM2 as a functional driver of invasion in adenocarcinoma. The study used protein-level profiling to move beyond gene-expression-only classification. Subtype stratification based on proteomic patterns can better capture pathway activity differences that drive clinical behavior and treatment responsiveness. In parallel, identifying CCM2 as a driver provides a concrete target for downstream validation and therapeutic exploration. For translational teams, the operational point is that proteomic subtyping may enable more precise risk modeling and trial enrichment, particularly where cervical cancer biology varies across histologic and molecular groups. The discovery also strengthens the case for integrating protein networks into clinical biomarker pipelines, since protein drivers are often closer to druggable mechanisms than upstream transcripts alone.